Establishment of an allergic rhinitis model in mice for the evaluation of nasal symptoms.
The purpose of our study was to establish a new model of allergic rhinitis in mice, eliciting symptoms such as sneezing, infiltration of eosinophils into the nasal mucosa, and antigen-specific IgE production. One of the major human T-cell epitopes in Cry j 1, an allergen of Japanese cedar pollen, is also a major murine T-cell epitope in B10.S mice. Thus we tried to establish an allergic rhinitis model in B10.S mice with Cry j 1 as the antigen. We sensitized B10.S mice subcutaneously with Cry j 1/alum three times at intervals of 1 week. Five weeks after the final sensitization, we challenged the mice by instilling Cry j 1 intranasally from the day after intranasal histamine pretreatment. Soon after, we counted the number of sneezes. We then evaluated the infiltration of eosinophils into the nasal tissues and also measured the serum levels of antigen-specific IgE antibody. In addition, we confirmed the effects of ketotifen fumarate and dexamethasone hydrochloride on these animals. In Cry j 1-sensitized B10.S mice, sneezes, eosinophil peroxidase (EPO) activity in nasal tissues, and Cry j 1-specific IgE clearly increased after intranasal histamine pretreatment and 5 days of continuous intranasal Cry j 1 challenge. Both ketotifen and dexamethasone inhibited the increase in sneezing, and dexamethasone also inhibited EPO activity and Cry j 1-specific IgE. Thus we succeeded in establishing a new model of allergic rhinitis in Cry j 1-sensitized B10.S mice, which exhibited sneezing, eosinophil infiltration into the nasal mucosa, and Cry j 1-specific IgE production.
Tsunematsu
Masako
M
Research and Development Center, Division of Research and Development, Meiji Dailies Corporation, 540 Naruda, Odawara, Kanagawa 250-0862, Japan. MASAKO_TSUNEMATSU@MEIJI-MILK.COM
Yamaji
Taketo
T
Kozutsumi
Daisuke
D
Murakami
Rika
R
Kimura
Shigeki
S
Kino
Kohsuke
K
D000818:Animals; D018926:Anti-Allergic Agents / Q000494:pharmacology; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D000941:Antigens / Q000276:immunology; D032485:Cryptomeria; D003907:Dexamethasone / Q000494:pharmacology; D004195:Disease Models, Animal; D004804:Eosinophils / Q000201:enzymology / Q000473:pathology; D005260:Female; D006632:Histamine / Q000494:pharmacology; D007114:Immunization; D007073:Immunoglobulin E / Q000276:immunology; D007665:Ketotifen / Q000494:pharmacology; D051379:Mice; D009297:Nasal Mucosa / Q000473:pathology*; D010544:Peroxidases / Q000378:metabolism; D011058:Pollen / Q000276:immunology; D006255:Rhinitis, Allergic, Seasonal / Q000276:immunology / Q000473:pathology*; D012912:Sneezing / Q000187:drug effects
D018926:Anti-Allergic Agents; D000893:Anti-Inflammatory Agents; D000941:Antigens; D007073:Immunoglobulin E; D003907:Dexamethasone; D006632:Histamine; D010544:Peroxidases; D007665:Ketotifen